comprehensive -WSS

comprehensive

author：focus 2025-09-28 23:11:11 - browse：63

U.S. President Joe Biden stands with his fingers locked next to an US flag — politics coverage from STAT — President Biden's White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs.

WASHINGTON — The White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs, its latest effort to draw attention to the program in an election year.

The news is not controversial: The pharmaceutical companies that make the first ten drugs up for negotiation all submitted counteroffers. It’s an incremental step in the new program, which was created in 2022.

Earlier this year, Medicare sent its initial price offers to the companies. Neither the Biden administration nor the drug manufacturers have volunteered any information about the White House’s initial price offers or the counteroffers. The process is scheduled to end by Aug. 1.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Kellogg’s is going to war over Mexico’s nutrition label rules

hotspot

focus

WSS

The United States must get value

How to make over

Trans patients at the end of life deserve respect and dignity

Abortion policy in the spotlight at Republican debate

How the first Native Hawaiian psychiatrist helped diversify medicine

STAT reporters are Pulitzer Prize finalists for investigative reporting

knowledge

comprehensive

hotspot

Medicare details structure of new drug price negotiation program

Hospital at home shows how to bring innovation to health care

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

STAT series 'Denied by AI' wins major journalism prizes

Affirmative action in medical school literally saved lives

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

As demand for Covid shots wanes, Moderna seeks its next success

Fertility clinic egg and embryo storage is a disaster

In age of alternative facts, a scholarly course on calling out crap

Abbott's new stent may help patients with peripheral artery disease

hotspot

Intellia plays down concerns on accidental germline transmission

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Novo Nordisk testing Wegovy against alcohol

Former Pear Therapeutics executives start new VC firm

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

National associations that represent hospice owe an apology

hotspot

explore

focus

entertainment